Sino Biopharmaceutical ( (HK:1177) ) has issued an update.
Sino Biopharmaceutical Limited announced that its application for a clinical trial of TQB6411, an EGFR/c-Met bispecific ADC, has been accepted by China’s Center for Drug Evaluation. TQB6411 is designed to target lung cancer driver genes, offering a potential treatment by blocking key signaling pathways and inducing cell death. The company has completed extensive pharmacological and safety verifications, showing promising results in vitro and in vivo. Alongside TQB6411, Sino Biopharmaceutical is also developing other drugs targeting EGFR and c-Met, highlighting its commitment to providing better treatment options for cancer patients worldwide.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a company in the pharmaceutical industry, focusing on the development of innovative drugs. Its primary products include antibody-drug conjugates (ADCs) and inhibitors targeting cancer-related genes such as EGFR and c-Met. The company aims to address unmet clinical needs globally by advancing its pipeline of cancer therapies.
YTD Price Performance: 16.41%
Average Trading Volume: 1,958
Technical Sentiment Signal: Sell
Current Market Cap: $9.27B
See more insights into 1177 stock on TipRanks’ Stock Analysis page.